Can a new drug combo outsmart resistant lymphomas?
NCT ID NCT07744750
First seen Aug 04, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This phase II trial is testing whether a combination of two targeted drugs—pirtobrutinib and sonrotoclax—can shrink tumors in people with three types of B-cell lymphoma: transformed diffuse large B-cell lymphoma, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, and relapsed or refractory marginal zone lymphoma. Some participants will also receive a third drug, obinutuzumab. The study will measure how many people respond to treatment and how long the benefit lasts, while also checking safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pirtobrutinib combined with sonrotoclax, with or without obinutuzumab
- What this could lead to
- If successful, this combination could offer a new, more effective treatment option for people with certain B-cell lymphomas that have returned or stopped responding to prior therapy.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The combination may also cause side effects, and not everyone will respond.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLL / SLL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jiangsu Province Hospital The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Pronged attack beat brain lymphoma?
- Can a targeted drug boost standard chemo for aggressive lymphoma?
- Can a targeted drug combo outsmart an aggressive lymphoma?
- Can a reshaped chemo combo tame lymphoma with fewer side effects?
- Can a Chemo-Free pill combo outsmart leukemia at first diagnosis?
- Engineered immune cells take on tough lymphomas